SGMO vs. CRIS, AGEN, DTIL, BLUE, LIFE, ALVR, PLX, VIGL, CVM, and ATRA
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Curis (CRIS), Agenus (AGEN), Precision BioSciences (DTIL), bluebird bio (BLUE), aTyr Pharma (LIFE), AlloVir (ALVR), Protalix BioTherapeutics (PLX), Vigil Neuroscience (VIGL), CEL-SCI (CVM), and Atara Biotherapeutics (ATRA). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 3.0% of Sangamo Therapeutics shares are held by insiders. Comparatively, 4.8% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Sangamo Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500.
Curis has lower revenue, but higher earnings than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Curis received 246 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Curis an outperform vote while only 62.75% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics currently has a consensus target price of $4.93, indicating a potential upside of 921.78%. Curis has a consensus target price of $37.33, indicating a potential upside of 154.14%. Given Sangamo Therapeutics' higher possible upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Curis.
Sangamo Therapeutics has a net margin of -146.30% compared to Curis' net margin of -473.04%. Sangamo Therapeutics' return on equity of -82.17% beat Curis' return on equity.
In the previous week, Sangamo Therapeutics had 2 more articles in the media than Curis. MarketBeat recorded 6 mentions for Sangamo Therapeutics and 4 mentions for Curis. Sangamo Therapeutics' average media sentiment score of 0.39 beat Curis' score of 0.20 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Summary
Sangamo Therapeutics beats Curis on 9 of the 17 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
